Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse.
about
Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac DeathCrosstalk between the heart and peripheral organs in heart failureTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesTargeting interleukin-1 in heart diseaseEnhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failureInteraction between interleukin-1 beta and angiotensin II receptor 1 in hypothalamic paraventricular nucleus contributes to progression of heart failureAlterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouseEffects of exercise training on pulmonary vessel muscularization and right ventricular function in an animal model of COPDIL-1β receptor antagonist reduces inflammation in hemodialysis patientsHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerAn expanding role for interleukin-1 blockade from gout to cancer.Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.The Importance of NLRP3 Inflammasome in Heart FailureTargeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial InfarctionDeleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction.The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarctionMyocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulusTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction.Interleukin-18 and IL-18 binding protein.Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol.Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor γ enhances myocardial ischemia-reperfusion injury in miceTreating inflammation by blocking interleukin-1 in humans.Interleukin-18 mediates interleukin-1-induced cardiac dysfunction.Blocking interleukin-1β in acute and chronic autoinflammatory diseases.Sensing damage by the NLRP3 inflammasome.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.Targeting interleukin-1 in heart failure and inflammatory heart disease.Predicting therapeutic response in patients with heart failure: the story of C-reactive protein.The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.L5-LDL from ST-elevation myocardial infarction patients induces IL-1β production via LOX-1 and NLRP3 inflammasome activation in macrophages.Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus.Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.Omega 3 fatty acid inhibition of inflammatory cytokine-mediated Connexin43 regulation in the heart.Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse.Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction.Complement-induced activation of the cardiac NLRP3 inflammasome in sepsis.Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells.
P2860
Q26744359-8C64053B-0CD3-46F7-BD05-3B329DFBC01AQ26766491-F1EC21CB-FF6F-4F21-8C19-B5E03AD32221Q26799747-98E5DA0A-7F00-44C7-AF23-B16BD9FEDBAAQ27009347-9534AC19-2926-468B-9564-F6C39D623A3EQ28731260-81FC4225-7092-4749-85D8-172E35482B6CQ30399909-2113E3BD-E32B-42FF-B517-84CFCA637B29Q34091132-CBDEC666-EA2E-497F-AA25-57C665E24EF6Q34273933-28E9D29A-FD6E-45CD-B50A-A1C475F4B923Q34695324-A200CB95-042B-42CD-9533-6C663257B7CFQ35016934-1119B1F1-5CF4-42D6-92FE-6F48B95F7C41Q35219001-16ABD8C3-2163-4995-92CC-16A2A5F09BC3Q35847003-259669E5-0D64-4631-8B1C-061CBDCD061FQ35855691-1FA65565-0AAE-4EBA-B5C7-EE675910EB37Q35891957-0047AD82-ED28-4939-A554-AF9F1A72568BQ36296699-E291594D-9536-4816-B846-324E25D289CDQ36522680-7B2D37E5-9206-4EA7-A314-E3A9CAC55CB9Q36609441-E6048069-E487-4DE3-918B-5EC739F4598BQ36762903-F72B016F-C377-454D-BDC8-76ABD14D1B45Q36816872-D02C3CCE-71C3-46FE-87CC-1A0738172243Q37187482-3BCCA9A2-65DA-43E3-8EAA-9C015569B82CQ37220336-3EF4490D-3E6D-4EF3-B25C-5328B3A9C326Q37402717-0B676D00-633D-41D6-9797-49C3FDA5C7FAQ37547865-F7A5C569-B1F8-408A-BA95-2D82DE073069Q37636664-8AF9EF2F-2090-4817-8337-7BD799A5DDD8Q37656103-B5D7CD5B-86F8-40FB-8911-A187EB14A3FEQ37821071-5B5C5D5E-B4C3-48F7-A8FB-D8CB13485363Q37925073-55A66CA1-49EC-4169-AE73-D7FC95F1D939Q38008700-82406B6A-BDF9-478A-9DBD-2BDA53E62315Q38260179-9A895753-E5EE-43DD-8B39-E047A926A1F8Q38314153-3867F5DC-B1F7-485C-88DE-7892A7F2EC18Q38389302-86E8686E-6AFF-4201-983C-1CE770DD3A8DQ38730205-C6B4F653-1AE0-4D48-BA14-32F9E3797C29Q38846401-7FF6EC57-2D74-405C-855F-DC92E9F2E852Q39403443-4B673AFC-8F89-48F4-8D67-A9115382B002Q41068150-6C46F69C-3E6B-4D8B-ACB3-1FCF233FCC08Q42321518-024A4F80-2B03-4357-B266-4F4F9AEA9F00Q44980873-1968EF4D-6EE5-427D-90D0-68F7E4C48D61Q46173512-8E09041D-FD22-4145-AEE4-CAEBDDE08398Q46499624-71D85436-5C2D-4240-BDA3-E7DB7DEEECF7Q47639049-8AD300DC-95B0-44D6-A652-F9480392AA94
P2860
Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@en
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@nl
type
label
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@en
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@nl
prefLabel
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@en
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@nl
P2093
P921
P356
P1476
Interleukin-1beta modulation u ...... rdial infarction in the mouse.
@en
P2093
Amit Varma
Antonio Abbate
Benjamin W Van Tassell
Fadi N Salloum
Ignacio M Seropian
Lisa Smithson
Roshanak Robati
P304
P356
10.1093/EURJHF/HFQ017
P577
2010-04-01T00:00:00Z